Board Member
Nurix Therapeutics, Inc. (NRIX)Equibles does not estimate personal net worth.
Get an email with a short summary when Nurix Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get NRIX alertsArthur T. Sands is recorded as Board Member and CEO at Nurix Therapeutics, Inc. (NRIX). The newest filing on record that lists Arthur T. Sands as Board Member and CEO at Nurix Therapeutics, Inc. (NRIX) is dated March 27, 2026. The proxy statement of Nurix Therapeutics, Inc. reports total compensation of $6,374,138 for Arthur T. Sands in fiscal 2025, including a base salary of $674,584. Disclosed compensation is on record for 7 fiscal years. Arthur T. Sands has spoken on 4 investor events across 1 company, most recently for Nurix Therapeutics, Inc. on September 16, 2026. Nurix Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nurix Therapeutics, Inc. includes Hans van Houte (CFO), Stefani Wolff (COO), Christine Ring (General Counsel) and 7 others.
“It's a landmark deal, I think, for the field of targeted protein degradation. And in B-cell malignancies and autoimmune disease, two therapeutic area deal, that's number one.”
“Yeah, well, the latest is we're coming upon EHA, European Hematology Association, conference, essentially next week in Stockholm. We'll have an oral presentation there.”
“The advantage of targeted protein degrader in the space in CLL and in BTK, we're seeing advantages expand and grow. So I can tell you where we started and now where we think it is, which is quite exciting.”
“Yeah, so we've reported at ASH most recently an 83% overall response rate in fourth line plus patients. So very advanced patients with CLL. So a very significant ORR.”
Start not stated–present
Last confirmed March 27, 2026
Start not stated–present
Last confirmed March 27, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Nurix Therapeutics, Inc. (NRIX) | President, Chief Executive Officer and Director | $674,584 | $6,374,138 |
| 2024 | Nurix Therapeutics, Inc. (NRIX) | President, Chief Executive Officer and Director | $613,104 | $5,812,862 |
| 2023 | Nurix Therapeutics, Inc. (NRIX) | President, Chief Executive Officer and Director | $590,813 | $4,363,120 |
| 2022 | Nurix Therapeutics, Inc. (NRIX) | President, Chief Executive Officer and Director | $572,083 | $9,416,222 |
| 2021 | Nurix Therapeutics, Inc. (NRIX) | M.D., Ph.D. President, Chief Executive Officer and Director | $538,750 | $4,791,466 |
| 2020 | Nurix Therapeutics, Inc. (NRIX) | M.D., Ph.D. President, Chief Executive Officer and Director | $521,167 | $16,867,841 |
| 2019 | Nurix Therapeutics, Inc. (NRIX) | M.D., Ph.D. President, Chief Executive Officer and Director | $477,833 | $1,481,610 |
